(Q28243804)

28

0 references

Hans-Peter Hartung

7

0 references

Ludwig Kappos

1

Ludwig Kappos

0 references

Howard L. Weiner

23

Howard L Weiner

0 references

Ralf Gold

25

Ralf Gold

0 references

Stephen L. Hauser

20

Stephen Hauser

0 references

Mads Ravnborg

15

Mads Ravnborg

0 references

author name string

David Bates

2

0 references

Gilles Edan

3

0 references

Mefkûre Eraksoy

4

0 references

Antonio Garcia-Merino

5

0 references

Nikolaos Grigoriadis

6

0 references

Eva Havrdová

8

0 references

Jan Hillert

9

0 references

Reinhard Hohlfeld

10

0 references

Marcelo Kremenchutzky

11

0 references

Olivier Lyon-Caen

12

0 references

Ariel Miller

13

0 references

Carlo Pozzilli

14

0 references

Takahiko Saida

16

0 references

Christian Sindic

17

0 references

Karl Vass

18

0 references

David B Clifford

19

0 references

Eugene O Major

21

0 references

Paul W O'Connor

22

0 references

Michel Clanet

24

0 references

Hans H Hirsch

26

0 references

Ernst-Wilhelm Radü

27

0 references

John King

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

29

0 references

language of work or name

English

0 references

publication date

August 2011

0 references

published in

Lancet Neurology

0 references

volume

10

0 references

issue

8

0 references

page(s)

745-58

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Anti-JC virus antibodies: implications for PML risk stratification

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab induces a rapid improvement of disability status and ambulation after failure of previous therapy in relapsing-remitting multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Efficacy and tolerability of natalizumab in relapsing-remitting multiple sclerosis patients: a post-marketing observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Melanoma complicating treatment with natalizumab for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Association of melanoma and natalizumab therapy in the Italian MS population: a second case report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

More on melanoma with transdifferentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Another complication of natalizumab treatment? Taking the challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab and central nervous system lymphoma: no clear association

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Primary central nervous system lymphoma in a patient treated with natalizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Allergic and nonallergic delayed infusion reactions during natalizumab therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Epilepsia partialis continua in progressive multifocal leukoencephalopathy: a motor cortex isolation syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

New cases of progressive multifocal leukoencephalopathy after treatment with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

New insights into progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Asymptomatic reactivation of JC virus in patients treated with natalizumab

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Assessment of JC virus DNA in blood and urine from natalizumab-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Reemergence of PML in natalizumab-treated patients--new cases, same concerns

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Assay design and sample collection can affect anti-John Cunningham virus antibody detection

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy in HIV-infected patients in the era of HAART: radiological features at diagnosis and follow-up and correlation with clinical variables

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy in a haploidentical stem cell transplant recipient: a clinical, neuroradiological and virological response after treatment with risperidone

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Progression of progressive multifocal leukoencephalopathy despite treatment with beta-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Immune reconstitution associated with progressive multifocal leukoencephalopathy in human immunodeficiency virus: a case discussion and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

Management and preparedness for infusion and hypersensitivity reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970149-1

7 January 2021

10.1016/S1474-4422(11)70149-1

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

21777829

1 reference

Consolidated OpenCitations Corpus – April 2017